Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes. Issue 5 (October 2019)

• Record Type: Journal Article
• Authors: Endo-Tsukude, Chihiro; Kato, Motohiro; Kaneko, Akihisa; Iida, Satofumi; Kuramoto, Shino; Ishigai, Masaki; Hamada, Akinobu
• Is Part Of: Drug metabolism and pharmacokinetics. Volume 34:Issue 5(2019)
• Page Start: 325
• Page End: 333
• Publication Date: 2019-10
• Subjects: CYP2C9 -- CYP3A4 -- Enzyme induction -- Hepatocyte -- Clinical study; Drugs -- Metabolism -- Periodicals; Pharmacokinetics -- Periodicals; 615.7
• DOI: 10.1016/j.dmpk.2019.07.002
• Languages: English
• ISSNs: 1347-4367

Abstract

Abstract: By using the Relative Factor (RF) method—a method that can simply assess cytochrome P450 (CYP) induction risk based on a maximum induction effect model—we evaluated the risk of CYP2C9 induction and examined its relationship with risk of CYP3A4 induction. In cryopreserved human hepatocytes, the magnitude of CYP2C9 induction by eight drugs known to induce CYP3A4 was lower than the magnitude of CYP3A4 induction, but the magnitudes of induction of both were correlated. The RF values determined for CYP2C9 had a one-to-one linear relationship with values determined for CYP3A4, supporting reports that the induction mechanism of both enzymes is the same. Furthermore, clinical CYP2C9 induction data of compounds reported to induce CYP2C9 clinically were shown to be lower than those of CYP3A4. The thresholds for CYP2C9 induction risk assessment by the RF approach were determined to be at higher steady-state plasma concentrations than those for CYP3A4. Based on these results, induction of CYP2C9 was correlated with that of CYP3A4, and induction risk could be evaluated by the RF method using hepatocytes. The CYP2C9 induction risk of a compound was confirmed to be lower than its CYP3A4 induction risk. Graphical abstract: Image 1